for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Affimed NV

AFMD.OQ

Latest Trade

3.43USD

Change

-0.20(-5.51%)

Volume

331,411

Today's Range

3.36

 - 

3.68

52 Week Range

2.53

 - 

5.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.63
Open
3.63
Volume
331,411
3M AVG Volume
16.18
Today's High
3.68
Today's Low
3.36
52 Week High
5.08
52 Week Low
2.53
Shares Out (MIL)
62.44
Market Cap (MIL)
214.00
Forward P/E
-6.63
Dividend (Yield %)
--

Latest Developments

More

Affimed NV Q2 Revenue EUR 4.0 Million Versus EUR 200,000

Affimed Announces Positive Clinical Data On AFM13 In CD30+ Lymphoma

Affimed Announces Research And Development Strategy To Focus On Innate Immunity Portfolio Reports First Quarter 2019 Financial Results And Operational Progress

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Affimed NV

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry

Biotechnology & Drugs

Contact Info

Im Neuenheimer Feld 582

+49.6221.674360

https://www.affimed.com/

Executive Leadership

Thomas Hecht

Chairman of the Supervisory Board

Adi Hoess

Chief Executive Officer, Member of the Management Board

Florian Fischer

Chief Financial Officer, Member of the Management Board

Wolfgang Fischer

Chief Operating Officer, Member of the Management Board

Martin Treder

Chief Scientific Officer, Member of the Management Board

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.970

2017

-0.690

2018

-0.320

2019(E)

-0.336
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.06
Price To Book (MRQ)
5.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.80
LT Debt To Equity (MRQ)
0.98
Return on Investment (TTM)
-19.16
Return on Equity (TTM)
-14.81

Latest News

Swiss stocks - Factors to watch on Aug 28

The Swiss blue-chip SMI was seen opening 0.1 percent higher at 9,107 points on Tuesday, according to premarket indications by bank Julius Baer .

BRIEF-Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics

* AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS

BRIEF-Affimed Reports Q4 Loss Per Share EUR 0.14

* AFFIMED REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR END 2017

BRIEF-Affimed Appoints Dr. Leila Alland As Chief Medical Officer

* AFFIMED NV - APPOINTMENT OF LEILA ALLAND TO POSITION OF CHIEF MEDICAL OFFICER (CMO), EFFECTIVE MARCH 26 Source text for Eikon: Further company coverage:

BRIEF-Affimed prices 11.5 mln common shares at $2 per share

* AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Affimed Announces Proposed Public Offering Of Common Stock

* AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials

* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

BRIEF-Affimed reports Q3 loss per share EUR 0.18

* Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S

BRIEF-Affimed announces Q3 financial results and corporate update conference call

* Affimed announces third quarter 2017 financial results and corporate update conference call Source text for Eikon: Further company coverage:

BRIEF-Affimed posts Q2 loss of EUR 0.18 per share

* Q2 earnings per share view EUR -0.20 -- Thomson Reuters I/B/E/S

BRIEF-Affimed reports Q1 loss per share EUR 0.19

* Q1 earnings per share view eur -0.21 -- Thomson Reuters I/B/E/S

BRIEF-Affimed reports Q4 loss per share EUR 0.16

* Affimed reports financial results for fourth quarter and year end 2016

BRIEF-Affimed announces closing of public offering of common stock

* Affimed announces closing of public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Affimed says public offering of 10 mln common shares priced at $1.80/shr

* Affimed announces pricing of public offering of common stock

BRIEF-Affimed announces proposed public offering of common stock

* Affimed announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Affimed, MD Anderson to collaborate on clinical immuno-oncology development

* Affimed and MD Anderson announce clinical immuno-oncology development collaboration

BRIEF-Affimed NV files to say it may offer and sell its common shares of up to $50 mln

* Files to say it may offer and sell its common shares of up to $50 million, from time to time, through Cowen, acting as agent Source text: [http://bit.ly/2hzerf7] Further company coverage:

BRIEF-Affimed reports financial results for third quarter 2016

* Affimed nv says has decided to advance afm24, an egfrwt/cd16a tandab, in solid tumors

BRIEF-Affimed reports Q3 loss per share eur 0.31

* Q3 earnings per share view eur -0.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up